Bioline RX Ltd (NASDAQ:BLRX) investors are cheering the news that the company has signed an exclusive, worldwide agreement with BGN Technologies, the Technology Transfer …
Bioline RX Ltd (NASDAQ:BLRX) announced its corporate objectives at an ongoing investor breakfast meeting at theConvene Conference Center near Grand Central in New York …
Bioline RX Ltd (NASDAQ:BLRX) announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients …
Bioline RX Ltd (NASDAQ:BLRX) announced that the successful final results of BL-8040’s Phase 2a clinical trial in relapsed or refractory acute myeloid leukemia (r/r …
Bioline RX Ltd (NASDAQ:BLRX) announced that it has entered into a collaboration with Genentech, a member of the Roche Group, to support several Phase …
Bioline RX Ltd (NASDAQ:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has established …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the signing of a collaboration …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed an …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the filing of regulatory submissions …
Bioline RX Ltd (NASDAQ:BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed a …